Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05229679
Other study ID # 2020-00053
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 16, 2020
Est. completion date December 31, 2038

Study information

Verified date October 2023
Source Karolinska Institutet
Contact Joakim Dillner, MD, PhD
Phone +46 (0) 72-468 24 60
Email joakim.dillner@ki.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the trial is to determine whether organized screening with primary HPV analysis provide higher cancer protection in the age group 23-29 years compared to primary cytology.


Description:

The aim is to investigate whether primary HPV analysis in the organized cell sampling program for women in the age group 23-29 provides higher cancer protection compared to the current method where cell samples are primarily analyzed with cytology. In this study, all women in the age group 23-29 in the Stockholm and Skåne Region of Sweden will participate. Age is defined by year of birth. For 2020, women born 1991-1997 are included. Sampling and collection of samples is the same as for cytology.


Recruitment information / eligibility

Status Recruiting
Enrollment 180000
Est. completion date December 31, 2038
Est. primary completion date December 31, 2038
Accepts healthy volunteers No
Gender Female
Age group 23 Years to 29 Years
Eligibility Inclusion Criteria: - Women ages 23-29 invited to screening. Exclusion Criteria: - Women who do not show up for screening or do not consent.

Study Design


Intervention

Diagnostic Test:
HPV testing
All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.

Locations

Country Name City State
Sweden Region of Skåne Lund Skåne
Sweden Region Stockholm Stockholm

Sponsors (1)

Lead Sponsor Collaborator
Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of cervical cancer Cervical cancer incidence in the intervention group compared to a historical control group. Measured once during 1 year, year 1.
Primary Incidence of cervical cancer Cervical cancer incidence in the intervention group compared to a historical control group. Measured once during 1 year, year 2.
Primary Incidence of cervical cancer Cervical cancer incidence in the intervention group compared to a historical control group. Measured once during 1 year, year 3.
Primary Incidence of cervical cancer Cervical cancer incidence in the intervention group compared to a historical control group. Measured once during 1 year, year 4.
Primary Incidence of cervical cancer Cervical cancer incidence in the intervention group compared to a historical control group. Measured once during 1 year, year 5.
Primary Incidence of cervical cancer Cervical cancer incidence in the intervention group compared to a historical control group. Measured once during 1 year, year 6.
Primary Incidence of cervical cancer Cervical cancer incidence in the intervention group compared to a historical control group. Measured once during 1 year, year 7.
Primary Incidence of cervical cancer Cervical cancer incidence in the intervention group compared to a historical control group. Measured once during 1 year, year 8.
Primary Incidence of cervical cancer Cervical cancer incidence in the intervention group compared to a historical control group. Measured once during 1 year, year 9.
Primary Incidence of cervical cancer Cervical cancer incidence in the intervention group compared to a historical control group. Measured once during 1 year, year 10.
Secondary Cost-effectiveness of the new screening method Cost-effectiveness of HPV-based screening among women 23-29 as compared to cytology-based screening in the same age group. Cost data will be collected from the economy system used for the administration of the study, and compared to previous cost data. Measured once during 1 year, year 1.
Secondary Cost-effectiveness of the new screening method Cost-effectiveness of HPV-based screening among women 23-29 as compared to cytology-based screening in the same age group. Cost data will be collected from the economy system used for the administration of the study, and compared to previous cost data. Measured once during 1 year, year 2.
Secondary Cost-effectiveness of the new screening method Cost-effectiveness of HPV-based screening among women 23-29 as compared to cytology-based screening in the same age group. Cost data will be collected from the economy system used for the administration of the study, and compared to previous cost data. Measured once during 1 year, year 3.
Secondary Cost-effectiveness of the new screening method Cost-effectiveness of HPV-based screening among women 23-29 as compared to cytology-based screening in the same age group. Cost data will be collected from the economy system used for the administration of the study, and compared to previous cost data. Measured once during 1 year, year 4.
Secondary Cost-effectiveness of the new screening method Cost-effectiveness of HPV-based screening among women 23-29 as compared to cytology-based screening in the same age group. Cost data will be collected from the economy system used for the administration of the study, and compared to previous cost data. Measured once during 1 year, year 5.
Secondary Cost-effectiveness of the new screening method Cost-effectiveness of HPV-based screening among women 23-29 as compared to cytology-based screening in the same age group. Cost data will be collected from the economy system used for the administration of the study, and compared to previous cost data. Measured once during 1 year, year 6.
Secondary Cost-effectiveness of the new screening method Cost-effectiveness of HPV-based screening among women 23-29 as compared to cytology-based screening in the same age group. Cost data will be collected from the economy system used for the administration of the study, and compared to previous cost data. Measured once during 1 year, year 7.
Secondary Cost-effectiveness of the new screening method Cost-effectiveness of HPV-based screening among women 23-29 as compared to cytology-based screening in the same age group. Cost data will be collected from the economy system used for the administration of the study, and compared to previous cost data. Measured once during 1 year, year 8.
Secondary Cost-effectiveness of the new screening method Cost-effectiveness of HPV-based screening among women 23-29 as compared to cytology-based screening in the same age group. Cost data will be collected from the economy system used for the administration of the study, and compared to previous cost data. Measured once during 1 year, year 9.
Secondary Cost-effectiveness of the new screening method Cost-effectiveness of HPV-based screening among women 23-29 as compared to cytology-based screening in the same age group. Cost data will be collected from the economy system used for the administration of the study, and compared to previous cost data. Measured once during 1 year, year 10.
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A